论文部分内容阅读
目的:检测作为当前靶向治疗中的生物抑制剂EGFR,c-Met和HER2/neu3种抗体在12例脊索瘤中的表达。方法:对12例脊索瘤和包含17种其他肿瘤(共51个样本)的多肿瘤组织阵列切片进行免疫组化法的蛋白表达以及相关分析。结果:大多数脊索瘤显示EGFR和C-Met的过度表达,而c-Erb-B2的表达差异较大,并且EGFR和C-Met的表达存在显著的关联性(P=0.006)。结论:脊索瘤像其他实体瘤一样,也表达EGFR,c-Met和HER2/neu3种抗体,大部分脊索瘤对EGFR和C-Met的表达程度较高。EGFR抑制剂已在其他实体瘤进行临床试验,并为进行顽固性脊索瘤临床试验提供了理论依据。
OBJECTIVE: To examine the expression of EGFR, c-Met and HER2 / neu3 antibodies in 12 chordomas as a bio-inhibitor in current targeted therapy. Methods: Immunohistochemical staining and correlation analysis of multiple tumor tissue array sections from 12 chordomas and 17 other tumors (51 samples in total) were performed. RESULTS: Most of the chordoma showed overexpression of EGFR and C-Met, while the expression of c-Erb-B2 was significantly different. There was also a significant correlation between the expression of EGFR and C-Met (P = 0.006). Conclusion: Chordoma, like other solid tumors, also expresses EGFR, c-Met and HER2 / neu3 antibodies. Most chordomas express higher levels of EGFR and C-Met. EGFR inhibitors have been tested in other solid tumors and provide a theoretical basis for the clinical trials of intractable chordoma.